000142857 001__ 142857
000142857 005__ 20240229112531.0
000142857 0247_ $$2doi$$a10.1016/j.cgh.2018.04.015
000142857 0247_ $$2pmid$$apmid:29660527
000142857 0247_ $$2ISSN$$a1542-3565
000142857 0247_ $$2ISSN$$a1542-7714
000142857 0247_ $$2altmetric$$aaltmetric:51241931
000142857 037__ $$aDKFZ-2019-00487
000142857 041__ $$aeng
000142857 082__ $$a610
000142857 1001_ $$aBläker, Hendrik$$b0
000142857 245__ $$aThe Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
000142857 260__ $$aNew York, NY$$bElsevier Science$$c2019
000142857 3367_ $$2DRIVER$$aarticle
000142857 3367_ $$2DataCite$$aOutput Types/Journal article
000142857 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1552383260_25417
000142857 3367_ $$2BibTeX$$aARTICLE
000142857 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142857 3367_ $$00$$2EndNote$$aJournal Article
000142857 520__ $$aColorectal tumors with mutations in BRAF and microsatellite stability (MSS) have been associated with adverse outcomes of patients. Combined tests for microsatellite instability-high (MSI-H) and BRAF mutations might therefore be used in risk assessment, particularly for patients with stage II tumors. We investigate the stage-specific prognostic value of combined testing for MSI-H and BRAF for patients with colorectal cancer.We performed a retrospective analysis of colorectal tumor samples collected from 1995 patients at 22 hospitals in Germany, between 2003 and 2010. Samples were analyzed for MSI-H using an established mononucleotide marker panel; BRAF mutations (BRAFV600E) were detected by Sanger sequencing or in tissue microarray blocks using immunohistochemistry. Cancers were assigned to categories of having MSS without mutations in BRAF, MSS with mutant BRAF, MSI-H without mutations in BRAF, and MSI-H with mutant BRAF. We investigated the association between tumor categories with clinical and pathologic features and patient's overall, disease-specific, and recurrence-free survival (median follow-up time, 5.1 y).Tumors were stage I in 364 (18%), stage II in 678 (34%), stage III in 673 (34%), and stage IV (14%) in 280 patients. Sixty-three percent of tumors were located in the colon and 37% in the rectum. Most tumors (85%) had MSS without mutations in BRAF, 3% had MSS with mutant BRAF, 7% had MSI-H without mutations in BRAF, and 5% had MSI-H with mutant BRAF. In patients whose tumors were MSI-H, mutation of BRAF did not significantly affect survival time. Patients whose tumors had MSS with mutant BRAF had significantly reduced overall survival (hazard ratio [HR], 2.16; 95% CI, 1.54-3.04; P < .001), disease-specific survival (HR, 2.59; 95% CI, 1.77-3.79; P < .001), and recurrence-free survival (HR, 2.45; 95% CI, 1.70-3.52; P < .001) than patients whose tumors had MSS without BRAF mutation. Although BRAF mutations in tumors with MSS were associated with disease-specific survival of patients with stage III or IV tumors (P < .001), these features did not affect survival of patients with stage II tumors (P = .639).In an analysis of almost 2000 patients with colorectal cancer, we found BRAF mutations to reduce survival of patients in stage III or IV (but not stage II) tumors with MSS. These findings do not support testing stage I or II colorectal tumors for BRAF mutations, although additional large studies are needed.
000142857 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000142857 588__ $$aDataset connected to CrossRef, PubMed,
000142857 7001_ $$0P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aAlwers, Elizabeth$$b1$$udkfz
000142857 7001_ $$aArnold, Alexander$$b2
000142857 7001_ $$aHerpel, Esther$$b3
000142857 7001_ $$aTagscherer, Katrin E$$b4
000142857 7001_ $$aRoth, Wilfried$$b5
000142857 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b6$$udkfz
000142857 7001_ $$0P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aWalter, Viola$$b7$$udkfz
000142857 7001_ $$aKloor, Matthias$$b8
000142857 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b9$$udkfz
000142857 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b10$$udkfz
000142857 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b11$$eLast author$$udkfz
000142857 773__ $$0PERI:(DE-600)2102638-5$$a10.1016/j.cgh.2018.04.015$$gVol. 17, no. 3, p. 455 - 462.e6$$n3$$p455 - 462.e6$$tClinical gastroenterology and hepatology$$v17$$x1542-3565$$y2019
000142857 909CO $$ooai:inrepo02.dkfz.de:142857$$pVDB
000142857 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142857 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000142857 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000142857 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000142857 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000142857 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000142857 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000142857 9141_ $$y2019
000142857 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN GASTROENTEROL H : 2017
000142857 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142857 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142857 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142857 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142857 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142857 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142857 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142857 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN GASTROENTEROL H : 2017
000142857 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000142857 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x1
000142857 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000142857 9201_ $$0I:(DE-He78)L501-20160331$$kL501$$lDKTK Frankfurt$$x3
000142857 980__ $$ajournal
000142857 980__ $$aVDB
000142857 980__ $$aI:(DE-He78)C070-20160331
000142857 980__ $$aI:(DE-He78)C020-20160331
000142857 980__ $$aI:(DE-He78)L101-20160331
000142857 980__ $$aI:(DE-He78)L501-20160331
000142857 980__ $$aUNRESTRICTED